Literature DB >> 7861706

Differences in hormonal and renal vascular responses between normotensive patients with autosomal dominant polycystic kidney disease and unaffected family members.

B J Barrett1, R Foley, J Morgan, D Hefferton, P Parfrey.   

Abstract

We tested the hypothesis that overactivity of the renal and systemic renin-angiotensin system is important to the pathogenesis of hypertension in autosomal dominant polycystic kidney disease (ADPKD). Up to 21 normotensive subjects with ADPKD and creatinine clearance > 70 ml/min/1.73 m2 were compared to 12 unaffected controls from the same families. Blood pressure, serum chemistry, sodium excretion, plasma renin and serum aldosterone and atrial natriuretic peptide (ANP) levels were measured at baseline, after acute sodium depletion, and after chronic higher sodium intake with and without enalapril. Effective renal plasma flow was measured by paraaminohippurate clearance in the higher sodium state, before and during an intravenous infusion of angiotensin II at 3 ng/kg/min. This was to test whether, by analogy to non-modulating essential hypertension, renal blood flow would fall to a lesser extent in the ADPKD subjects. The groups were comparable at baseline apart from a higher supine mean arterial pressure in the ADPKD group (median 91 vs. 81 mm Hg, P = 0.002). There were no significant differences between ADPKD and control subjects in blood pressure or hormonal response to sodium depletion. During chronically higher sodium intake, serum ANP was significantly higher (median 130 vs. 81 ng/liter, P = 0.0006) and plasma renin tended to be higher (median 20.5 vs. 13.5, P = 0.08) in ADPKD than in control subjects. The ADPKD group had a higher renal vascular resistance (median 7420 vs. 5915 dyn.sec.cm-5, P = 0.009) before angiotensin, but tended to have a lower percentage rise in resistance during angiotensin (median 31.5 vs. 46, P = 0.14).(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7861706     DOI: 10.1038/ki.1994.374

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  13 in total

1.  Kidney dysfunction following adrenalectomy in autosomal dominant polycystic kidney disease complicated with primary aldosteronism: A case report.

Authors:  Hiroyuki Hirai; Makoto Kanno; Tsuyoshi Watanabe; Hiroaki Satoh
Journal:  Exp Ther Med       Date:  2017-06-13       Impact factor: 2.447

2.  Effect of statin therapy on disease progression in pediatric ADPKD: design and baseline characteristics of participants.

Authors:  Melissa A Cadnapaphornchai; Diana M George; Amirali Masoumi; Kim McFann; John D Strain; Robert W Schrier
Journal:  Contemp Clin Trials       Date:  2011-01-23       Impact factor: 2.226

3.  Peripheral augmentation index and vascular inflammation in autosomal dominant polycystic kidney disease.

Authors:  Kevin S Heffernan; Jeffrey T Kuvin; Mark J Sarnak; Ronald D Perrone; Dana C Miskulin; Darya Rudym; Priya Chandra; Richard H Karas; Vandana Menon
Journal:  Nephrol Dial Transplant       Date:  2011-02-03       Impact factor: 5.992

4.  Angiogenic growth factors correlate with disease severity in young patients with autosomal dominant polycystic kidney disease.

Authors:  Berenice Y Reed; Amirali Masoumi; Elwaleed Elhassan; Kim McFann; Melissa A Cadnapaphornchai; David M Maahs; Janet K Snell-Bergeon; Robert W Schrier
Journal:  Kidney Int       Date:  2010-09-29       Impact factor: 10.612

5.  Coronary flow velocity reserve and carotid intima media thickness in patients with autosomal dominant polycystic kidney disease: from impaired tubules to impaired carotid and coronary arteries.

Authors:  Kultigin Turkmen; Huseyin Oflaz; Bora Uslu; Arif O Cimen; Ali Elitok; Erdem Kasikcioglu; Sabahat Alisir; Fatih Tufan; Sule Namli; Mukremin Uysal; Tevfik Ecder
Journal:  Clin J Am Soc Nephrol       Date:  2008-03-19       Impact factor: 8.237

6.  Pravastatin Therapy and Biomarker Changes in Children and Young Adults with Autosomal Dominant Polycystic Kidney Disease.

Authors:  Jelena Klawitter; Kim McFann; Alexander T Pennington; Wei Wang; Jost Klawitter; Uwe Christians; Robert W Schrier; Berenice Gitomer; Melissa A Cadnapaphornchai
Journal:  Clin J Am Soc Nephrol       Date:  2015-07-29       Impact factor: 8.237

Review 7.  Cardiovascular abnormalities in autosomal-dominant polycystic kidney disease.

Authors:  Tevfik Ecder; Robert W Schrier
Journal:  Nat Rev Nephrol       Date:  2009-04       Impact factor: 28.314

8.  Bioactive lipid mediators in polycystic kidney disease.

Authors:  Jelena Klawitter; Jost Klawitter; Kim McFann; Alexander T Pennington; Kaleab Z Abebe; Godela Brosnahan; Melissa A Cadnapaphornchai; Michel Chonchol; Berenice Gitomer; Uwe Christians; Robert W Schrier
Journal:  J Lipid Res       Date:  2013-12-16       Impact factor: 5.922

9.  Polycystin 2-dependent cardio-protective mechanisms revealed by cardiac stress.

Authors:  Esther Giehl; Fernanda O Lemos; Yan Huang; Frank J Giordano; Ivana Y Kuo; Barbara E Ehrlich
Journal:  Pflugers Arch       Date:  2017-07-31       Impact factor: 3.657

10.  Association between Nephrolithiasis, Hypertension and Obesity in Polycystic Kidney Disease.

Authors:  Valbona Bajrami; Alma Idrizi; Enver Roshi; Myftar Barbullushi
Journal:  Open Access Maced J Med Sci       Date:  2015-12-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.